Beneficial Ownership Report · SCHEDULE 13G/A
Twist Bioscience Corporation
TWSTNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- TWIST BIOSCIENCE CORP
- Company CIK
- 0001581280
- Street
- 681 GATEWAY BLVD
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Statement details
- Amendment number
- 2
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- FMR LLC
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 9,535,192.79
- Percent of class
- 14.4
- Sole voting power
- 9,519,320.88
- Shared voting power
- 0.00
- Sole dispositive power
- 9,535,192.79
- Shared dispositive power
- 0.00
Reporting person 2
- Name
- Abigail P. Johnson
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 9,535,192.79
- Percent of class
- 14.4
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 9,535,192.79
- Shared dispositive power
- 0.00
Item 1
Issuer
TWIST BIOSCIENCE CORP
Principal executive office address
681 GATEWAY BLVD,South San Francisco,CA,United States,94080
Item 2
Citizenship
Not applicable
Filing person
FMR LLC
Principal business or residence address
245 Summer Street, Boston, Massachusetts 02210
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
14.4
Amount beneficially owned
9535192.79
Sole voting power
Please see the responses to Items 5 and 6 on the cover page.
Shared voting power
0.00
Sole dispositive power
9535192.79
Shared dispositive power
0.00
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TWIST BIOSCIENCE CORP. The interest of Fidelity Global Innovators Investment Trust, in the COMMON STOCK of TWIST BIOSCIENCE CORP, amounted to 3476508.00 shares or 5.2% of the total outstanding COMMON STOCK at 09/30/2026.
Item 7
Not applicable indication
N
Subsidiaries
See attached Exhibit 99.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Please see Exhibit 99 for 13d-1(k) (1) agreement.
Signature comments
* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Signature 1
- Reporting person
- FMR LLC
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
- Date
- 11/04/2026
Signature 2
- Reporting person
- Abigail P. Johnson
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
- Date
- 11/04/2026
Filed exhibits
- EX-99 ↗exhibit99.txt
Company context
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.